Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118406) titled 'Prospective Phase II Clinical Study of Neoadjuvant Therapy with Disitamab Vedotin Combined with Radiotherapy, Sintilimab, and Capecitabine for HER2-Overexpressing Locally Advanced Gastric Cancer' on Feb. 5.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Jiangsu Cancer Hospital

Condition: Gastric Cancer

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2025-12-19

Target Sample Size: Intervention Group:35;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=286620

Disclaimer: Curated by HT Syndication....